Literature DB >> 33803255

Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies.

Gratiela Gradisteanu Pircalabioru1, Nicolae Corcionivoschi2, Ozan Gundogdu3, Mariana-Carmen Chifiriuc1,4, Luminita Gabriela Marutescu1, Bogdan Ispas1, Octavian Savu5,6.   

Abstract

Globally, we are facing a worrying increase in type 1 diabetes mellitus (T1DM) incidence, with onset at younger age shedding light on the need to better understand the mechanisms of disease and step-up prevention. Given its implication in immune system development and regulation of metabolism, there is no surprise that the gut microbiota is a possible culprit behind T1DM pathogenesis. Additionally, microbiota manipulation by probiotics, prebiotics, dietary factors and microbiota transplantation can all modulate early host-microbiota interactions by enabling beneficial microbes with protective potential for individuals with T1DM or at high risk of developing T1DM. In this review, we discuss the challenges and perspectives of translating microbiome data into clinical practice. Nevertheless, this progress will only be possible if we focus our interest on developing numerous longitudinal, multicenter, interventional and double-blind randomized clinical trials to confirm their efficacy and safety of these therapeutic approaches.

Entities:  

Keywords:  diet; dysbiosis; microbiome; microbiota; type 1 diabetes

Mesh:

Year:  2021        PMID: 33803255      PMCID: PMC7967220          DOI: 10.3390/ijms22052763

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  118 in total

1.  Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.

Authors:  Karen M Lammers; Ruliang Lu; Julie Brownley; Bao Lu; Craig Gerard; Karen Thomas; Prasad Rallabhandi; Terez Shea-Donohue; Amir Tamiz; Sefik Alkan; Sarah Netzel-Arnett; Toni Antalis; Stefanie N Vogel; Alessio Fasano
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

Review 2.  Omics-based biomarkers in the diagnosis of diabetes.

Authors:  Wei Zien Gan; Valsala Ramachandran; Crystale Siew Ying Lim; Rhun Yian Koh
Journal:  J Basic Clin Physiol Pharmacol       Date:  2019-11-14

3.  Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies.

Authors:  Anette-G Ziegler; Sandra Schmid; Doris Huber; Michael Hummel; Ezio Bonifacio
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

4.  Maternal and neonatal risk factors for childhood type 1 diabetes: a matched case-control study.

Authors:  Lynn Robertson; Kirsten Harrild
Journal:  BMC Public Health       Date:  2010-05-27       Impact factor: 3.295

5.  Type 2 Diabetes Mellitus: Integrative Analysis of Multiomics Data for Biomarker Discovery.

Authors:  Siqi Ge; Youxin Wang; Manshu Song; Xingang Li; Xinwei Yu; Hao Wang; Jing Wang; Qiang Zeng; Wei Wang
Journal:  OMICS       Date:  2018-07

6.  Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study.

Authors:  Isabel Leiva-Gea; Lidia Sánchez-Alcoholado; Beatriz Martín-Tejedor; Daniel Castellano-Castillo; Isabel Moreno-Indias; Antonio Urda-Cardona; Francisco J Tinahones; José Carlos Fernández-García; María Isabel Queipo-Ortuño
Journal:  Diabetes Care       Date:  2018-09-17       Impact factor: 19.112

Review 7.  A model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes.

Authors:  Austin G Davis-Richardson; Eric W Triplett
Journal:  Diabetologia       Date:  2015-05-10       Impact factor: 10.122

8.  Fecal microbiota imbalance in Mexican children with type 1 diabetes.

Authors:  María Esther Mejía-León; Joseph F Petrosino; Nadim Jose Ajami; María Gloria Domínguez-Bello; Ana María Calderón de la Barca
Journal:  Sci Rep       Date:  2014-01-22       Impact factor: 4.379

9.  An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.

Authors:  Jun Chen; Kerry Wright; John M Davis; Patricio Jeraldo; Eric V Marietta; Joseph Murray; Heidi Nelson; Eric L Matteson; Veena Taneja
Journal:  Genome Med       Date:  2016-04-21       Impact factor: 11.117

Review 10.  Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review.

Authors:  Bingbing Li; Xuyun He; Wei Jia; Houkai Li
Journal:  Molecules       Date:  2017-07-13       Impact factor: 4.411

View more
  4 in total

Review 1.  Pathogenesis of Type 1 Diabetes: Established Facts and New Insights.

Authors:  Ana Zajec; Katarina Trebušak Podkrajšek; Tine Tesovnik; Robert Šket; Barbara Čugalj Kern; Barbara Jenko Bizjan; Darja Šmigoc Schweiger; Tadej Battelino; Jernej Kovač
Journal:  Genes (Basel)       Date:  2022-04-16       Impact factor: 4.141

Review 2.  Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy.

Authors:  Pratima Singh Thakur; David Aggarwal; Brijesh Takkar; Sisinthy Shivaji; Taraprasad Das
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-07-08       Impact factor: 4.925

3.  Gut microbiota diversity in middle-aged and elderly patients with end-stage diabetic kidney disease.

Authors:  Rongping Chen; Dan Zhu; Rui Yang; Zezhen Wu; Ningning Xu; Fengwu Chen; Shuo Zhang; Hong Chen; Ming Li; Kaijian Hou
Journal:  Ann Transl Med       Date:  2022-07

4.  Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes mellitus.

Authors:  Lina He; Rongping Chen; Bangzhou Zhang; Shuo Zhang; Barkat Ali Khan; Dan Zhu; Zezhen Wu; Chuanxing Xiao; Baolong Chen; Fengwu Chen; Kaijian Hou
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.